Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Outset Medical, Inc. (NASDAQ: OM) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. Outset is a medical technology manufacturer focused on the Tablo Hemodialysis System, and its filings offer detail on financial performance, risk factors, and the business model behind its dialysis platform.
Among the key documents, investors can review Form 10-K annual reports and Form 10-Q quarterly reports, which typically include discussions of product revenue from Tablo consoles, recurring revenue from Tablo consumables and services, gross margin trends, operating expenses, and liquidity. These filings also reference the risks and uncertainties that could affect Outset’s results and the regulatory environment in which it operates.
Outset’s Form 8-K current reports are particularly relevant for tracking material events. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter financial results and updated or revised revenue guidance. Such filings summarize the nature of the event and incorporate the related press release by reference.
On this page, users can also monitor insider transaction reports on Form 4, proxy statements on Schedule 14A when available, and other submissions that shed light on governance, executive compensation, and ownership changes.
Stock Titan enhances these filings with AI-powered summaries that explain the main points of lengthy documents, highlight notable changes from prior periods, and surface items such as revenue mix, margin commentary, and forward-looking statements. Real-time updates from EDGAR help ensure that new OM filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 insider reports, are quickly reflected and summarized for easier review.
BML Investment Partners, L.P.Outset Medical, Inc. common stock on a Schedule 13G. BML disclosed beneficial ownership of 1,705,876 shares of common stock, representing 9.4% of the outstanding class.
BML reported shared voting and dispositive power over all 1,705,876 shares, with no sole voting or dispositive authority. The filing is signed by Braden M. Leonard on behalf of BML Capital Management, LLC, the general partner of BML Investment Partners, L.P., and notes that Leonard is deemed an indirect owner of these shares. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Outset Medical, indicating a passive investment intent.
Outset Medical EVP Marc Nash reported selling 108 shares of common stock on January 7, 2026 at $4.27 per share. This small sale was a required "sell to cover" transaction to satisfy tax withholding on 289 shares of common stock earned under performance stock units that vested and were released on January 6, 2025, rather than a discretionary trade. Following this transaction, Nash beneficially owned 48,160 shares of Outset Medical common stock directly.
Outset Medical, Inc. reported that its General Counsel, John L. Brottem, sold 224 shares of common stock on January 7, 2026 at $4.27 per share. According to the disclosure, this was a required sale to cover tax withholding tied to 447 shares of common stock underlying performance stock units that had been earned based on performance criteria and vested on January 6, 2025. After this sell-to-cover transaction, Brottem beneficially owned 46,271 shares of Outset Medical common stock. The filing states that the transaction was executed as a “sell to cover” for taxes and does not represent a discretionary trade by the reporting person.
Outset Medical, Inc. Chair and CEO Leslie Trigg reported a sale of 1,795 shares of Common Stock on January 7, 2026 at $4.27 per share. According to the footnote, this was a required "sell to cover" transaction to satisfy tax withholding on 4,904 shares underlying performance stock units that were earned based on performance criteria and vested and released on January 6, 2025, so it was not a discretionary trade.
After this transaction, Trigg beneficially owned 119,617 shares directly, plus 41,666 shares held indirectly through the Trigg 2002 Rev Trust and 584 shares held indirectly through the Trigg Family Trust.
OM stockholder filed a Form 144 to plan the sale of 108 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $461.16 and 18,153,090 shares of common stock outstanding.
The 108 shares to be sold were acquired on 01/06/2026 through settlement of 289 vested performance stock units from the issuer as equity compensation for services rendered, with payment also on 01/06/2026. During the prior three months, the same seller, listed as Marc Nash, sold 247 shares of common stock on 11/17/2025 for gross proceeds of $1,136.20. The signer represents that they are not aware of any undisclosed material adverse information about OM’s operations.
A security holder named Leslie Trigg has filed a Rule 144 notice indicating an intention to sell 1,795 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ exchange around 01/07/2026. The filing notes that there were 18,153,090 shares of this class of common stock outstanding.
The securities to be sold are linked to 4,904 shares acquired on 01/06/2026 through settlement of vested performance stock units as equity compensation for services. Over the prior three months, the same holder sold 916 shares of common stock on 11/17/2025 for gross proceeds of $4,213.60. By signing the notice, the seller represents that they are not aware of undisclosed material adverse information about the issuer’s operations.
A shareholder of OM has filed a Rule 144 notice to sell 224 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $956.48. The filing notes that 18,153,090 shares of this class were outstanding and lists an approximate sale date of 01/07/2026.
The securities to be sold were acquired on 01/06/2026 through settlement of 447 vested performance stock units as equity compensation for services rendered. The form also reports that John Brottem sold 388 shares of OM common stock on 11/17/2025 for gross proceeds of $1,784.80. The person for whose account the securities are to be sold represents that they are not aware of any undisclosed material adverse information about OM’s operations.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
